Global Markets Direct’s, ‘Relapsed Multiple Myeloma – Pipeline Review, H1 2015’, provides an overview of the Relapsed Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Relapsed Multiple Myeloma Overview 10
Therapeutics Development 11
Pipeline Products for Relapsed Multiple Myeloma - Overview 11
Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis 12
Relapsed Multiple Myeloma - Therapeutics under Development by Companies 13
Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 17
Relapsed Multiple Myeloma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Relapsed Multiple Myeloma - Products under Development by Companies 20
Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes 25
Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development 26
4SC AG 26
AB Science 27
AbbVie Inc. 28
Acceleron Pharma, Inc. 29
Acetylon Pharmaceuticals, Inc. 30
Altor BioScience Corporation 31
Arno Therapeutics, Inc. 32
Array BioPharma Inc. 33
Astellas Pharma Inc. 34
Astex Pharmaceuticals, Inc. 35
Biotest AG 36
Bristol-Myers Squibb Company 37
Celgene Corporation 38
Cellectar Biosciences, Inc. 39
Chroma Therapeutics Ltd. 40
CureTech Ltd. 41
Curis, Inc. 42
Exelixis, Inc. 43
F. Hoffmann-La Roche Ltd. 44
GlaxoSmithKline plc 45
Immunomedics, Inc. 46
Johnson & Johnson 47
Karyopharm Therapeutics, Inc. 48
MedImmune, LLC 49
Merck & Co., Inc. 50
Millennium Pharmaceuticals, Inc. 51
MorphoSys AG 52
Novartis AG 53
Noxxon Pharma AG 54
Oncolytics Biotech Inc. 55
Oncopeptides AB 56
Onyx Pharmaceuticals, Inc. 57
Patrys Limited 58
Pfizer Inc. 59
Pharma Mar, S.A. 60
Pharmacyclics, Inc. 61
Prolexys Pharmaceuticals, Inc. 62
Sanofi 63
Sevion Therapeutics, Inc. 64
Stemline Therapeutics, Inc. 65
Sumitomo Dainippon Pharma Co., Ltd. 66
Synta Pharmaceuticals Corp. 67
Threshold Pharmaceuticals, Inc. 68
Vivolux AB 69
Relapsed Multiple Myeloma - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 77
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
4SC-202 - Drug Profile 85
ACP-196 - Drug Profile 87
afuresertib hydrochloride - Drug Profile 89
alisertib - Drug Profile 91
alpelisib - Drug Profile 95
ALT-801 - Drug Profile 97
ALT-803 - Drug Profile 99
amrubicin hydrochloride - Drug Profile 101
AR-42 - Drug Profile 103
AT-7519 - Drug Profile 105
AT-9283 - Drug Profile 108
B-701 - Drug Profile 110
bendamustine hydrochloride - Drug Profile 111
cabozantinib s-malate - Drug Profile 114
carfilzomib - Drug Profile 117
CB-5083 - Drug Profile 121
CC-90002 - Drug Profile 122
Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile 123
CHR-3996 - Drug Profile 124
CUDC-907 - Drug Profile 125
dalantercept - Drug Profile 127
daratumumab - Drug Profile 129
dasatinib - Drug Profile 132
DKN-01 - Drug Profile 135
elotuzumab - Drug Profile 137
erismodegib - Drug Profile 139
evofosfamide - Drug Profile 142
filanesib - Drug Profile 149
ganetespib - Drug Profile 151
GSK-2857916 - Drug Profile 156
GSK-525762 - Drug Profile 157
I131-CLR1404 - Drug Profile 158
ibrutinib - Drug Profile 160
indatuximab ravtansine - Drug Profile 166
isatuximab - Drug Profile 168
ixazomib citrate - Drug Profile 170
LCL-161 - Drug Profile 173
LGH-447 - Drug Profile 175
linsitinib - Drug Profile 176
marizomib - Drug Profile 178
masitinib - Drug Profile 180
MEDI-551 - Drug Profile 183
Melflufen - Drug Profile 185
milatuzumab - Drug Profile 187
MLN-0128 - Drug Profile 189
MOR-202 - Drug Profile 191
MV-NIS - Drug Profile 193
olaptesed pegol - Drug Profile 195
oprozomib - Drug Profile 198
palbociclib - Drug Profile 200
panobinostat - Drug Profile 204
PATSM-6 - Drug Profile 210
pelareorep - Drug Profile 212
pembrolizumab - Drug Profile 217
pidilizumab - Drug Profile 223
plerixafor - Drug Profile 225
plitidepsin - Drug Profile 227
pomalidomide - Drug Profile 229
PRLX-93936 - Drug Profile 233
quisinostat - Drug Profile 235
Recombinant Protein for Oncology - Drug Profile 237
ricolinostat - Drug Profile 239
selinexor - Drug Profile 241
SL-401 - Drug Profile 245
SNS-01T - Drug Profile 247
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 248
ulocuplumab - Drug Profile 250
urelumab - Drug Profile 252
vemurafenib - Drug Profile 254
venetoclax - Drug Profile 258
VLX-1570 - Drug Profile 261
vorinostat - Drug Profile 262
Relapsed Multiple Myeloma - Recent Pipeline Updates 266
Relapsed Multiple Myeloma - Dormant Projects 418
Relapsed Multiple Myeloma - Discontinued Products 421
Relapsed Multiple Myeloma - Product Development Milestones 422
Featured News & Press Releases 422
Appendix 432
Methodology 432
Coverage 432
Secondary Research 432
Primary Research 432
Expert Panel Validation 432
Contact Us 432
Disclaimer 433

List of Tables

Number of Products under Development for Relapsed Multiple Myeloma, H1 2015 16
Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Development by Companies, H1 2015 (Contd..4) 29
Products under Investigation by Universities/Institutes, H1 2015 30
Relapsed Multiple Myeloma - Pipeline by 4SC AG, H1 2015 31
Relapsed Multiple Myeloma - Pipeline by AB Science, H1 2015 32
Relapsed Multiple Myeloma - Pipeline by AbbVie Inc., H1 2015 33
Relapsed Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2015 34
Relapsed Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 35
Relapsed Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2015 36
Relapsed Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H1 2015 37
Relapsed Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2015 38
Relapsed Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2015 39
Relapsed Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 40
Relapsed Multiple Myeloma - Pipeline by Biotest AG, H1 2015 41
Relapsed Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2015 42
Relapsed Multiple Myeloma - Pipeline by Celgene Corporation, H1 2015 43
Relapsed Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H1 2015 44
Relapsed Multiple Myeloma - Pipeline by Chroma Therapeutics Ltd., H1 2015 45
Relapsed Multiple Myeloma - Pipeline by CureTech Ltd., H1 2015 46
Relapsed Multiple Myeloma - Pipeline by Curis, Inc., H1 2015 47
Relapsed Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2015 48
Relapsed Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 49
Relapsed Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2015 50
Relapsed Multiple Myeloma - Pipeline by Immunomedics, Inc., H1 2015 51
Relapsed Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2015 52
Relapsed Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 53
Relapsed Multiple Myeloma - Pipeline by MedImmune, LLC, H1 2015 54
Relapsed Multiple Myeloma - Pipeline by Merck & Co., Inc., H1 2015 55
Relapsed Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 56
Relapsed Multiple Myeloma - Pipeline by MorphoSys AG, H1 2015 57
Relapsed Multiple Myeloma - Pipeline by Novartis AG, H1 2015 58
Relapsed Multiple Myeloma - Pipeline by Noxxon Pharma AG, H1 2015 59
Relapsed Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2015 60
Relapsed Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2015 61
Relapsed Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 62
Relapsed Multiple Myeloma - Pipeline by Patrys Limited, H1 2015 63
Relapsed Multiple Myeloma - Pipeline by Pfizer Inc., H1 2015 64
Relapsed Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2015 65
Relapsed Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2015 66
Relapsed Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015 67
Relapsed Multiple Myeloma - Pipeline by Sanofi, H1 2015 68
Relapsed Multiple Myeloma - Pipeline by Sevion Therapeutics, Inc., H1 2015 69
Relapsed Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H1 2015 70
Relapsed Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 71
Relapsed Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2015 72
Relapsed Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 73
Relapsed Multiple Myeloma - Pipeline by Vivolux AB, H1 2015 74
Assessment by Monotherapy Products, H1 2015 75
Assessment by Combination Products, H1 2015 76
Number of Products by Stage and Target, H1 2015 78
Number of Products by Stage and Mechanism of Action, H1 2015 83
Number of Products by Stage and Route of Administration, H1 2015 87
Number of Products by Stage and Molecule Type, H1 2015 89
Relapsed Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2015 271
Relapsed Multiple Myeloma - Dormant Projects, H1 2015 423
Relapsed Multiple Myeloma - Dormant Projects (Contd..1), H1 2015 424
Relapsed Multiple Myeloma - Dormant Projects (Contd..2), H1 2015 425
Relapsed Multiple Myeloma - Discontinued Products, H1 2015 426

List of Figures

Number of Products under Development for Relapsed Multiple Myeloma, H1 2015 16
Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Assessment by Monotherapy Products, H1 2015 75
Number of Products by Top 10 Targets, H1 2015 77
Number of Products by Stage and Top 10 Targets, H1 2015 77
Number of Products by Top 10 Mechanism of Actions, H1 2015 82
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82
Number of Products by Top 10 Routes of Administration, H1 2015 86
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 86
Number of Products by Top 10 Molecule Types, H1 2015 88
Number of Products by Stage and Top 10 Molecule Types, H1 2015 88